APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

TNF Inhibitors for the Treatment of Plaque Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Analysis and Forecast 2026-2032

Report ID 174041650227 December 2025204 pages

Choose your research edition.

Industry ResearchTNF Inhibitors for the Treatment of Plaque Psoriasis Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal TNF Inhibitors for the Treatment of Plaque Psoriasis Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global TNF Inhibitors for the Treatment of Plaque Psoriasis market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for TNF Inhibitors for the Treatment of Plaque Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of TNF Inhibitors for the Treatment of Plaque Psoriasis include Chia Tai Tianqing Pharmaceutical, Innovent Biologics, Sino Cell Technologies, Samsung Bioepis, Hangzhou Bozhirui Biopharmaceuticals, Hisun Pharmaceuticals, Bio-Thera Solutions, YL Biologics and UCB, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for TNF Inhibitors for the Treatment of Plaque Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of TNF Inhibitors for the Treatment of Plaque Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for TNF Inhibitors for the Treatment of Plaque Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the TNF Inhibitors for the Treatment of Plaque Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for TNF Inhibitors for the Treatment of Plaque Psoriasis sales, projected growth trends, production technology, application and end-user industry.

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Company

Chia Tai Tianqing Pharmaceutical

Innovent Biologics

Sino Cell Technologies

Samsung Bioepis

Hangzhou Bozhirui Biopharmaceuticals

Hisun Pharmaceuticals

Bio-Thera Solutions

YL Biologics

UCB

Teva

Sandoz

Pfizer

Janssen Biotech

Coherus BioSciences

Celltrion

Boehringer Ingelheim Pharmaceuticals

Biocon Biologics

Amgen

AbbVie

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Type

Adalimumab

Certolizumab pegol

Etanercept

Infliximab

Other

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

TNF Inhibitors for the Treatment of Plaque Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TNF Inhibitors for the Treatment of Plaque Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TNF Inhibitors for the Treatment of Plaque Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TNF Inhibitors for the Treatment of Plaque Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of TNF Inhibitors for the Treatment of Plaque Psoriasis in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of TNF Inhibitors for the Treatment of Plaque Psoriasis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, TNF Inhibitors for the Treatment of Plaque Psoriasis sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Adalimumab Major Manufacturers Table 3. Certolizumab pegol Major Manufacturers Table 4. Etanercept Major Manufacturers Table 5. Infliximab Major Manufacturers Table 6. Other Major Manufacturers Table 7. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital and Clinic Major Manufacturers Table 9. Retail Pharmacies Major Manufacturers Table 10. Other Major Manufacturers Table 11. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends Table 12. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers Table 13. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges Table 14. TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints Table 15. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 17. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 18. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2021-2026) Table 19. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2027-2032) Table 20. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2021-2026) & (K Units) Table 22. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2027-2032) & (K Units) Table 23. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region (2021-2026) Table 24. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region (2027-2032) Table 25. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Manufacturers (2021-2026) Table 27. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Manufacturers (2021-2026) Table 29. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers, Product Type & Application Table 33. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global TNF Inhibitors for the Treatment of Plaque Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 38. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 39. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2021-2026) Table 40. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2027-2032) Table 41. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2026) & (K Units) Table 43. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2027-2032) & (K Units) Table 44. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2021-2026) Table 45. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2027-2032) Table 46. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2021-2026) & (US$/Unit) Table 47. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2027-2032) & (US$/Unit) Table 48. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 50. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 51. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2021-2026) Table 52. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2027-2032) Table 53. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2026) & (K Units) Table 55. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2027-2032) & (K Units) Table 56. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2021-2026) Table 57. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2027-2032) Table 58. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2021-2026) & (US$/Unit) Table 59. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2027-2032) & (US$/Unit) Table 60. Chia Tai Tianqing Pharmaceutical Company Information Table 61. Chia Tai Tianqing Pharmaceutical Business Overview Table 62. Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 64. Chia Tai Tianqing Pharmaceutical Recent Development Table 65. Innovent Biologics Company Information Table 66. Innovent Biologics Business Overview Table 67. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 69. Innovent Biologics Recent Development Table 70. Sino Cell Technologies Company Information Table 71. Sino Cell Technologies Business Overview Table 72. Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 74. Sino Cell Technologies Recent Development Table 75. Samsung Bioepis Company Information Table 76. Samsung Bioepis Business Overview Table 77. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 79. Samsung Bioepis Recent Development Table 80. Hangzhou Bozhirui Biopharmaceuticals Company Information Table 81. Hangzhou Bozhirui Biopharmaceuticals Business Overview Table 82. Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 84. Hangzhou Bozhirui Biopharmaceuticals Recent Development Table 85. Hisun Pharmaceuticals Company Information Table 86. Hisun Pharmaceuticals Business Overview Table 87. Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 89. Hisun Pharmaceuticals Recent Development Table 90. Bio-Thera Solutions Company Information Table 91. Bio-Thera Solutions Business Overview Table 92. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 94. Bio-Thera Solutions Recent Development Table 95. YL Biologics Company Information Table 96. YL Biologics Business Overview Table 97. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 99. YL Biologics Recent Development Table 100. UCB Company Information Table 101. UCB Business Overview Table 102. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 104. UCB Recent Development Table 105. Teva Company Information Table 106. Teva Business Overview Table 107. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 109. Teva Recent Development Table 110. Sandoz Company Information Table 111. Sandoz Business Overview Table 112. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 114. Sandoz Recent Development Table 115. Pfizer Company Information Table 116. Pfizer Business Overview Table 117. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 119. Pfizer Recent Development Table 120. Janssen Biotech Company Information Table 121. Janssen Biotech Business Overview Table 122. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 124. Janssen Biotech Recent Development Table 125. Coherus BioSciences Company Information Table 126. Coherus BioSciences Business Overview Table 127. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 129. Coherus BioSciences Recent Development Table 130. Celltrion Company Information Table 131. Celltrion Business Overview Table 132. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 134. Celltrion Recent Development Table 135. Boehringer Ingelheim Pharmaceuticals Company Information Table 136. Boehringer Ingelheim Pharmaceuticals Business Overview Table 137. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 139. Boehringer Ingelheim Pharmaceuticals Recent Development Table 140. Biocon Biologics Company Information Table 141. Biocon Biologics Business Overview Table 142. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 144. Biocon Biologics Recent Development Table 145. Amgen Company Information Table 146. Amgen Business Overview Table 147. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 149. Amgen Recent Development Table 150. AbbVie Company Information Table 151. AbbVie Business Overview Table 152. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio Table 154. AbbVie Recent Development Table 155. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 156. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 157. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2026) & (K Units) Table 158. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2027-2032) & (K Units) Table 159. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 160. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 161. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 162. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 163. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2026) & (K Units) Table 164. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2027-2032) & (K Units) Table 165. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 166. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 167. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 169. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 170. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 171. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 172. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 173. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 174. North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 175. United States TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 176. Canada TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 177. Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 178. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 179. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 180. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2026) & (K Units) Table 181. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2027-2032) & (K Units) Table 182. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 183. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 184. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 185. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 186. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2026) & (K Units) Table 187. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2027-2032) & (K Units) Table 188. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 189. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 190. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 191. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 192. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 193. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 194. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 195. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 196. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 197. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 198. Germany TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 199. France TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 200. U.K. TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 201. Italy TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 202. Russia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 203. Spain TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 204. Netherlands TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 205. Switzerland TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 206. Sweden TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 207. Poland TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 208. China TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 209. China TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 210. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2026) & (K Units) Table 211. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2027-2032) & (K Units) Table 212. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 213. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 214. China TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 215. China TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 216. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2026) & (K Units) Table 217. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2027-2032) & (K Units) Table 218. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 219. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 220. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 221. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 222. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2026) & (K Units) Table 223. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2027-2032) & (K Units) Table 224. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 225. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 226. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 227. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 228. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2026) & (K Units) Table 229. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2027-2032) & (K Units) Table 230. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 231. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 232. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 233. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 234. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 235. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 236. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 237. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 238. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 239. Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 240. Japan TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 241. South Korea TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 242. India TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 243. Australia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 244. Taiwan TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 245. Southeast Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 246. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 247. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 248. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2026) & (K Units) Table 249. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2027-2032) & (K Units) Table 250. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 251. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 252. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 253. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 254. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2026) & (K Units) Table 255. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2027-2032) & (K Units) Table 256. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 257. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 258. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 259. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 260. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 261. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 262. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021-2026) & (K Units) Table 263. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2027-2032) & (K Units) Table 264. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 265. SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 266. Brazil TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 267. Argentina TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 268. Chile TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 269. Colombia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 270. Peru TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 271. Saudi Arabia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 272. Israel TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 273. UAE TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 274. Turkey TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 275. Iran TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 276. Egypt TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Table 277. Key Raw Materials Table 278. Raw Materials Key Suppliers Table 279. TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors List Table 280. TNF Inhibitors for the Treatment of Plaque Psoriasis Customers List Table 281. Research Programs/Design for This Report Table 282. Authors List of This Report Table 283. Secondary Sources Table 284. Primary Sources List of Figures Figure 1. TNF Inhibitors for the Treatment of Plaque Psoriasis Image Figure 2. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Share 2021 VS 2025 VS 2032 Figure 4. Adalimumab Image Figure 5. Certolizumab pegol Image Figure 6. Etanercept Image Figure 7. Infliximab Image Figure 8. Other Image Figure 9. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital and Clinic Image Figure 12. Retail Pharmacies Image Figure 13. Other Image Figure 14. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (2021-2032) & (US$ Million) Figure 16. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2021-2032) Figure 19. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales (2021-2032) & (K Units) Figure 20. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico TNF Inhibitors for the Treatment of Plaque Psoriasis Sales YoY (2021-2032) & (K Units) Figure 23. Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales YoY (2021-2032) & (K Units) Figure 24. China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) TNF Inhibitors for the Treatment of Plaque Psoriasis Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa TNF Inhibitors for the Treatment of Plaque Psoriasis Sales YoY (2021-2032) & (K Units) Figure 27. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global TNF Inhibitors for the Treatment of Plaque

Scope & coverage.

Types
  • Adalimumab
  • Certolizumab pegol
  • Etanercept
  • Infliximab
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Innovent Biologics
  • Sino Cell Technologies
  • Samsung Bioepis
  • Hangzhou Bozhirui Biopharmaceuticals
  • Hisun Pharmaceuticals
  • Bio-Thera Solutions
  • YL Biologics
  • UCB
  • Teva
  • Sandoz
  • Pfizer
  • Janssen Biotech
  • Coherus BioSciences
  • Celltrion
  • Boehringer Ingelheim Pharmaceuticals
  • Biocon Biologics
  • Amgen
  • AbbVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Type
  3. 1.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Adalimumab
  5. 1.2.3 Certolizumab pegol
  6. 1.2.4 Etanercept
  7. 1.2.5 Infliximab
  8. 1.2.6 Other
  9. 1.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Application
  10. 1.3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital and Clinic
  12. 1.3.3 Retail Pharmacies
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 TNF Inhibitors for the Treatment of Plaque Psoriasis Market Dynamics
  1. 2.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Trends
  2. 2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Drivers
  3. 2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Opportunities and Challenges
  4. 2.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region
  3. 3.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2021-2026)
  5. 3.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Region (2027-2032)
  6. 3.2.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Region (2021-2032)
  7. 3.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region
  9. 3.4.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2021-2026)
  11. 3.4.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Region (2027-2032)
  12. 3.4.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Manufacturers
  2. 4.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Manufacturers
  6. 4.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers, Product Type & Application
  13. 4.7 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market CR5 and HHI
  16. 4.8.2 2025 TNF Inhibitors for the Treatment of Plaque Psoriasis Tier 1, Tier 2, and Tier 3
5 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Type
  1. 5.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type
  2. 5.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Type (2021-2032)
  5. 5.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type
  6. 5.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Type (2021-2032)
  9. 5.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type
6 TNF Inhibitors for the Treatment of Plaque Psoriasis Market by Application
  1. 6.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application
  2. 6.1.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Market Share by Application (2021-2032)
  5. 6.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application
  6. 6.2.1 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Market Share by Application (2021-2032)
  9. 6.3 Global TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application
7 Company Profiles
  1. 7.1 Chia Tai Tianqing Pharmaceutical
  2. 7.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 7.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 7.1.3 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chia Tai Tianqing Pharmaceutical TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  6. 7.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 7.2 Innovent Biologics
  8. 7.2.1 Innovent Biologics Company Information
  9. 7.2.2 Innovent Biologics Business Overview
  10. 7.2.3 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Innovent Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  12. 7.2.5 Innovent Biologics Recent Developments
  13. 7.3 Sino Cell Technologies
  14. 7.3.1 Sino Cell Technologies Company Information
  15. 7.3.2 Sino Cell Technologies Business Overview
  16. 7.3.3 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sino Cell Technologies TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  18. 7.3.5 Sino Cell Technologies Recent Developments
  19. 7.4 Samsung Bioepis
  20. 7.4.1 Samsung Bioepis Company Information
  21. 7.4.2 Samsung Bioepis Business Overview
  22. 7.4.3 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Samsung Bioepis TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  24. 7.4.5 Samsung Bioepis Recent Developments
  25. 7.5 Hangzhou Bozhirui Biopharmaceuticals
  26. 7.5.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
  27. 7.5.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
  28. 7.5.3 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hangzhou Bozhirui Biopharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  30. 7.5.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
  31. 7.6 Hisun Pharmaceuticals
  32. 7.6.1 Hisun Pharmaceuticals Company Information
  33. 7.6.2 Hisun Pharmaceuticals Business Overview
  34. 7.6.3 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Hisun Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  36. 7.6.5 Hisun Pharmaceuticals Recent Developments
  37. 7.7 Bio-Thera Solutions
  38. 7.7.1 Bio-Thera Solutions Company Information
  39. 7.7.2 Bio-Thera Solutions Business Overview
  40. 7.7.3 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Bio-Thera Solutions TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  42. 7.7.5 Bio-Thera Solutions Recent Developments
  43. 7.8 YL Biologics
  44. 7.8.1 YL Biologics Company Information
  45. 7.8.2 YL Biologics Business Overview
  46. 7.8.3 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 YL Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  48. 7.8.5 YL Biologics Recent Developments
  49. 7.9 UCB
  50. 7.9.1 UCB Company Information
  51. 7.9.2 UCB Business Overview
  52. 7.9.3 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 UCB TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  54. 7.9.5 UCB Recent Developments
  55. 7.10 Teva
  56. 7.10.1 Teva Company Information
  57. 7.10.2 Teva Business Overview
  58. 7.10.3 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Teva TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  60. 7.10.5 Teva Recent Developments
  61. 7.11 Sandoz
  62. 7.11.1 Sandoz Company Information
  63. 7.11.2 Sandoz Business Overview
  64. 7.11.3 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Sandoz TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  66. 7.11.5 Sandoz Recent Developments
  67. 7.12 Pfizer
  68. 7.12.1 Pfizer Company Information
  69. 7.12.2 Pfizer Business Overview
  70. 7.12.3 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Pfizer TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  72. 7.12.5 Pfizer Recent Developments
  73. 7.13 Janssen Biotech
  74. 7.13.1 Janssen Biotech Company Information
  75. 7.13.2 Janssen Biotech Business Overview
  76. 7.13.3 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Janssen Biotech TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  78. 7.13.5 Janssen Biotech Recent Developments
  79. 7.14 Coherus BioSciences
  80. 7.14.1 Coherus BioSciences Company Information
  81. 7.14.2 Coherus BioSciences Business Overview
  82. 7.14.3 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Coherus BioSciences TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  84. 7.14.5 Coherus BioSciences Recent Developments
  85. 7.15 Celltrion
  86. 7.15.1 Celltrion Company Information
  87. 7.15.2 Celltrion Business Overview
  88. 7.15.3 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Celltrion TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  90. 7.15.5 Celltrion Recent Developments
  91. 7.16 Boehringer Ingelheim Pharmaceuticals
  92. 7.16.1 Boehringer Ingelheim Pharmaceuticals Company Information
  93. 7.16.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  94. 7.16.3 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Boehringer Ingelheim Pharmaceuticals TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  96. 7.16.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  97. 7.17 Biocon Biologics
  98. 7.17.1 Biocon Biologics Company Information
  99. 7.17.2 Biocon Biologics Business Overview
  100. 7.17.3 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Biocon Biologics TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  102. 7.17.5 Biocon Biologics Recent Developments
  103. 7.18 Amgen
  104. 7.18.1 Amgen Company Information
  105. 7.18.2 Amgen Business Overview
  106. 7.18.3 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Amgen TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  108. 7.18.5 Amgen Recent Developments
  109. 7.19 AbbVie
  110. 7.19.1 AbbVie Company Information
  111. 7.19.2 AbbVie Business Overview
  112. 7.19.3 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 AbbVie TNF Inhibitors for the Treatment of Plaque Psoriasis Product Portfolio
  114. 7.19.5 AbbVie Recent Developments
8 North America
  1. 8.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Type
  2. 8.1.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2032)
  3. 8.1.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032)
  4. 8.1.3 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2021-2032)
  5. 8.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Application
  6. 8.2.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2032)
  7. 8.2.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032)
  8. 8.2.3 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2021-2032)
  9. 8.3 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country
  10. 8.3.1 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Type
  2. 9.1.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2032)
  3. 9.1.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032)
  4. 9.1.3 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2021-2032)
  5. 9.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Application
  6. 9.2.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2032)
  7. 9.2.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032)
  8. 9.2.3 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2021-2032)
  9. 9.3 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country
  10. 9.3.1 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Type
  2. 10.1.1 China TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2032)
  3. 10.1.2 China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032)
  4. 10.1.3 China TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2021-2032)
  5. 10.2 China TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Application
  6. 10.2.1 China TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2032)
  7. 10.2.2 China TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032)
  8. 10.2.3 China TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Type
  2. 11.1.1 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2032)
  3. 11.1.2 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032)
  4. 11.1.3 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2021-2032)
  5. 11.2 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Application
  6. 11.2.1 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2032)
  7. 11.2.2 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032)
  8. 11.2.3 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2021-2032)
  9. 11.3 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country
  10. 11.3.1 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Type
  2. 12.1.1 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Type (2021-2032)
  4. 12.1.3 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Type (2021-2032)
  5. 12.2 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Application
  6. 12.2.1 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Application (2021-2032)
  8. 12.2.3 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Application (2021-2032)
  9. 12.3 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Market Size by Country
  10. 12.3.1 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA TNF Inhibitors for the Treatment of Plaque Psoriasis Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Value Chain Analysis
  2. 13.1.1 TNF Inhibitors for the Treatment of Plaque Psoriasis Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 TNF Inhibitors for the Treatment of Plaque Psoriasis Production Mode & Process
  6. 13.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 TNF Inhibitors for the Treatment of Plaque Psoriasis Distributors
  9. 13.2.3 TNF Inhibitors for the Treatment of Plaque Psoriasis Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst